Scientific Research

Motor Effects of 1,3-Disubstituted 8-Styrylxanthines as A_1 and A_2 Adenosine-Receptor Antagonists in Rats

Ilhuicamina Daniel Limón-Pérez de León[1*], María del Carmen Parra-Cid[2], Alejandro Muñoz-Zurita[1], Saúl Alejandro Merino-Contreras[1], Sara Montiel-Smith[1], Socorro Meza-Reyes[1], Gerardo Ramírez-Mejía[1], Jesús Sandoval-Ramírez[1]

[1]Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, México; [2]Instituto Nacional de Rehabilitación, Unidad de Ingeniería de Tejidos, Terapia Celular y Medicina Regenerativa, México DF, México.
Email: *ilhlimon@yahoo.com.mx

ABSTRACT

A series of 1,3-substituted 8-styrylxanthines (**11a-d**) was synthesized, under chemo- and regioselective conditions, in a good overall yield. The compounds showed affinity towards both A_1 and A_{2A}-adenosine receptors by radioligand binding by means of *in vitro* assays. The (*E*)-3-ethyl-1-propyl-8-styrylxanthine (**11a**) showed the greatest affinity towards the A_{2A} receptor, whereas (*E*)-3-pentyl-1-propyl-8-styrylxanthine (**11d**) showed the greatest affinity for the A_1 receptor. When the 8-styrylxanthines **11a (A15Et)** and **11c (A15Bu)** were administrated in rats, which were previously injured with 6-hydroxydopamine at the *substantia nigra pars compacta* (SNc), the turning behavior decreased 50%. Based on these results we propose to A15Et as a potential compound to treat some symptoms of Parkinson's disease.

Keywords: Xantines; Adenosine Receptors Antagonists; Turning Behavior; Anti-Parkinsonian Drugs

1. Introduction

The nucleoside adenosine exerts a modulatory influence on the central nervous system by the activation of the G-protein-coupled receptors, through a mechanism involving vasodilatation, inhibition of lipolysis, and insulin release [1,2]. Most of the actions of adenosine are mediated by four extra-cellular receptors [3] termed A_1, A_{2A}, A_{2B} and A_3. The activation of A_1 and A_3 receptors inhibits adenylate cyclase through G_i coupling, and activation of A_{2A} and A_{2B} receptors stimulates adenylate cyclase through G_s coupling [4]. The A_1 receptors are widely distributed throughout the brain, where they regulate neurotransmitter release and neuronal firing by activation of potassium channels. The distribution of A_{2A} is heterogeneous with high levels of expression in the *nucleus accumbens*, olfactory tubercle, *globus pallidus* and striatum [5,6] where A_{2A} receptors are co-localized with dopamine D_2 receptors in the *striato-pallidal* terminal [7]. The A_{2A}-D_2 interaction seems to be more potent in striatal dopamine denervation with supersensitive D_2 receptors [8]. This fact has been confirmed in the course of the

binding assay of the selective agonists and antagonists [6,8,9]. When considered together with the important role of dopamine in the control of motor activity and in the etiology and management of Parkinson's disease (PD), this observation suggested that adenosine A_{2A} receptors could be a novel target for drugs that manage movement disorders [9-11].

Results from recent PD studies on animal models suggest that antagonism of the A_{2A} receptor may also protect against underlying neuronal degenerative processes [9, 12].

The blockade of A_{2A} receptor reverses damage by excitotoxicity [13] and counteracts the motor deficits produced by dopaminergic toxin [14].

Recent preclinical and clinical data suggest that A_{2A} antagonist may provide a complementary therapy for PD [11,15,16]. Furthermore the A_{2A} receptor participates as a neuroprotector agent [12,14,15]. The (*E*)-8-(3-chlorostyryl)caffeine (CSC) has been employed as a selective inhibitor of the A_{2A} subtype of adenosine receptor [17]. However several analogues of CSC act as inhibitors of monoamino oxidase B (MAOB) [18-23]. Because of their role in the metabolism of monoamines and the

inhibition of MAOB, CSC is being used in preclinical studies for treatment of symptoms of PD [20-23].

Therefore the protective effect may be related to the ability of the A_{2A} antagonists to antagonize the increase of toxicity of glutamate induction by quinolinic acid. Recently, some researchers have proposed that the inhibitors of MAOB, caffeine and their derivatives reduce the risk of developing PD [23] and produce an anxiolytic effect [22]. Current data suggest that adenosine acts on dopamine regulation and dopaminergic function, and that the antagonists of the adenosinergic receptor decrease the dopaminergic activity [23].

For the above mentioned reasons, A_{2A} receptors have become important targets for development of drugs for the treatment of PD [10,23]. Some structures have shown affinity and selectivity towards A_{2A} receptors [9,19,24, 25], as xanthines, adenines, 1,2,4-triazolo[1,5-*a*]quinox-alines and pyrazolo[3,4-*d*]-pyrimidines (**Figure 1**). Pharmacological studies suggested that derivates of 8-styry-lxanthine have biological activity as an anti-Parkinsonian drug [26-28].

In this paper we report the synthesis, binding studies and pharmacology properties of 8-styrylxanthines. We found that (*E*)-3-ethyl-1-propyl-8-styrylxanthine (A15Et, compound **11a**) showed the greatest affinity for the A_{2A} receptor, also the biological experiments showed a decrease in the turning behavior, so we suggest that this compound represent a potential drug for treatment of Parkinson's disease.

2. Materials and Methods

2.1. Synthesis of Chemical Compounds

The melting points were measured with a Melt-temp apparatus and were not corrected. The NMR spectra were recorded on a Varian spectrometer; ^{1}H spectra at 400 MHz and ^{13}C at 100 MHz. DMSO-d_6 and CDCl$_3$ were used as solvents. All chemical shifts are quoted in ppm and the coupling constants are expressed in Hertz. The chemical shift of the remaining no deuterated protons of DMSO-d_6 served as an internal standard (δ ^{1}H: 2.50, ^{13}C: 39.7). The IR spectra were obtained from a Shimadzu FT-IR 8400 spectrophotometer, using KBr pellets; wave-numbers of maximum absorption peaks are reported as cm^{-1}. The UV spectra were recorded in a Perkin Elmer Lambda Bio 40 apparatus, using ethanol as solvent; λ_{max} is described in nm. TLC was performed on 60 F$_{254}$ silica gel plates.

2.1.1. Synthesis of 6-Amino-3-propyluracil (6)

A suspension of 6-aminouracil (**5**) (5.08 g, 40 mmol) and (NH$_4$)$_2$SO$_4$ (250 mg) in hexamethyldisilazane (14 mL, 60 mmol), was refluxed for 45 min. In this time the mixture became transparent indicating that all **5** was trisilylated. The crude was allowed to cool to 45°C; then, the *n*-propyl iodide (1.9 mL, 20 mmol) was added. The reaction was refluxed for 2 h. The crude was treated with an aqueous solution of Na$_2$S$_2$O$_3$ (6 g/20 mL). Additionally, a saturated aqueous solution of NaHCO$_3$ (20 mL) was added drop wise until effervescence ceased. The suspension obtained was filtered, and the white precipitate was washed with cold water, diethyl ether, and hexane. Yield: 92%; mp 267°C - 269°C (lit. 275°C). ^{1}H-NMR (DMSO-d_6) δ: 6.32 (2H, b, NH$_2$), 4.53 (1H, s, H-5), 3.59 (2H, t, EtCH$_2$N, *J* = 7.3 Hz), 1.46 (2H, m, MeCH$_2$CH$_2$N), 0.80, (3H, t, CH$_3$(CH$_2$)$_2$N, *J* = 7.3 Hz); ^{13}C-NMR (DMSO-d_6) δ: 163.7 (C-4), 154.5 (C-2), 151.9 (C-6), 74.7 (C-5), 40.2 (EtCH$_2$N), 21.5 (MeCH$_2$CH$_2$N), 11.7 (CH$_3$CH$_2$CH$_2$N); IR $\bar{v}_{max}$: 2930, 1741, 1631; UV $\lambda_{max}(\varepsilon)$: 261(3500).


Figure 1. Compounds showing selectivity towards A_{2A} receptors.

2.1.2. Synthesis of 6-Amino-5-nitroso-3-propyluracil (7)

The uracil **6** (0.84 g, 5 mmol) was dissolved in 80% aq AcOH (10 mL)/MeOH (15 mL) warm solution. The solution was cooled down to room temperature and a solution of $NaNO_2$ (0.69 g, 10 mmol) in water (5 mL) was added drop-wise. The yellow precipitate was collected by filtration and washed with water (2 × 20 mL) and diethyl ether (2 × 20 mL). Yield: 85%; mp > 300°C; ^{1}H-NMR (DMSO-d_6) δ: 11.37 (1H, b, H-N), 3.79 (2H, t, Et**CH$_2$**N, J = 7.3), 1.60 (2H, m, Me**CH$_2$**CH$_2$N), 0.89 (3H, t, **CH$_3$**CH$_2$CH$_2$N, J = 7.3); NMR ^{13}C (DMSO-d_6) δ: 161.8 (C-4), 150.3 (C-2), 145.5 (C-6), 140.3 (C-5), 40.2 (Et**CH$_2$**N), 21.4 (Me**CH$_2$**CH$_2$N), 11.8 (**CH$_3$**CH$_2$CH$_2$N); IR $\overline{v}_{max}$: 3294, 3185, 1511; UV $\lambda_{max}(\varepsilon)$: 320(5920).

2.1.3. Synthesis of 5,6-Diamino-3-propyluracil (8)

The nitroso compound **7** (10 mmol, 1.98 g) was dissolved in 6% aq NH_4OH (40 mL) at 80°C, then $Na_2S_2O_3$ (30 mmol, 3.5 g) was added in small portions. The solution decolorizes rapidly. The warm crude was concentrated under reduced pressure; a precipitate is produced. After filtration, the white precipitate was washed with a small amount of cold water (20 mL). Compound **8** is very sensitive to air and to $CDCl_3$ solutions, so it was immediately used in the following step. Yield: 69%.

2.1.4. Synthesis of (E)-6-amino-3-propyl-5-styrylcarboxamidouracil (9)

A suspension of the diamino compound **8** (7 mmol, 1.28 g), EDCl (7 mmol, 1.34 g), and (*E*)-cinnamic acid (7 mmol, 1.03 g) in CH_3OH (20 mL) was stirred at room temperature overnight. The precipitate obtained was collected by filtration, washed with MeOH, water, and diethyl ether. Yield: 76%; mp > 300°C; ^{1}H-NMR (DMSO-d_6) δ: 8.7 (1H, b, **H**N in styrylamido group), 7.41 (6H, m, aromatics and H-vinylic), 6.85 (1H, d, vinylic, J_{trans} = 16), 6.11 (2H, b, -N**H$_2$**), 3.6 (2H, t, CH$_3$CH$_2$**CH$_2$**N, J = 7.3), 1.5 (2H, m, CH$_3$**CH$_2$**CH$_2$N), 0.81 (3H, t, **CH$_3$**CH$_2$CH$_2$N, J = 7.3); ^{13}C-NMR (DMSO-d_6) δ: 165.6 (C=O in styrylamido group), 161.2 (C-4), 150.5 (C-6), 150.4 (C-2), 139.4 (Ph-H**C**=), 135.5 (C-*ipso*), 130.0 (C-*meta*), 129.6 (C-*orto*), 128.0 (C-*para*), 122.9 (=**CH**-), 87.7 (C-5), 40.2 (Et**CH$_2$**N), 21.5 (Me**CH$_2$**CH$_2$N), 11.8 (**CH$_3$**CH$_2$CH$_2$N); IR $\overline{v}_{max}$: 3318, 3187, 1648; UV $\lambda_{max}(\varepsilon)$: 280(6670).

2.1.5. General Procedure for the Preparation of 1-Substituted (E)-6-amino-3-propyl-5-styrylcarboxamidouracils 10a-d

Compound **9** (1 mmol, 0.314 g) was dissolved in DMF (3.5 mL), then K_2CO_3 (1.1 mmol, 0.16 g) and the alkyl halide (1.1 mmol) were added. The mixture was stirred at room temperature for 48 h and the progress of the reaction was monitored by TLC (eluent: acetone/hexane, 2:3). After addition of water (30 mL) a precipitate was produced, which was collected by filtration and washed with water (2 × 20 mL) and dried in a vacuum desiccator.

1) (E)-6-amino-1-ethyl-3-propyl-8-styrylcarboxamidouracil (10a)

Yield: 78%; mp 284°C - 286°C; ^{1}H-NMR (CDCl$_3$) δ: 8.04 (1H, b, N**H**), 7.63 (1H, d, -**CH**=), 7.36 (5H, m, aromatics), 6.70 (1H, d, -**CH**=), 5.83 (2H, b, -N**H$_2$**), 4.28, (2H, q, CH$_3$**CH$_2$**N), 4.12, (2H, t, CH$_3$CH$_2$**CH$_2$**N), 1.79 (2H, m, CH$_3$**CH$_2$**CH$_2$N), 1.42 (3H, t, **CH$_3$**CH$_2$N); 0.99 (3H, t, **CH$_3$**CH$_2$CH$_2$N); ^{13}C NMR (CDCl$_3$) δ: 166.0 (C=O styrylamido), 160.3 (C-4), 152.5 (C-6), 150.7 (C-2), 141.6 and 119.8 (-**CH**=**CH**-), 134.3, 129.6, 128.5, 127.7 (aromatics), 95.4 (C-5), 43.4 (CH$_3$CH$_2$**CH$_2$**N), 39.1 (CH$_3$**CH$_2$**N), 21.1 (CH$_3$**CH$_2$**CH$_2$N), 13.5 (**CH$_3$**CH$_2$N), 11.7 (**CH$_3$**CH$_2$CH$_2$N); IR $\overline{v}_{max}$: 3165, 1734, 1651, 968; UV (EtOH) $\lambda_{max}(\varepsilon)$: 278(11620).

2) (E)-6-amino-1,3-dipropyl-8-styrylcarboxamidouracil (10b)

Yield: 75%; mp 272°C - 273°C; ^{1}H-NMR (CDCl$_3$) δ: 8.40 (1H, b, N**H** styrylamido), 7.54 and 6.74 (d, 1H, -**CH**=**CH**-, J_{trans} = 16.4 Hz), 7.31 (m, 5H, aromatics), 6.11 (b, 2H, -N**H$_2$**), 4.14 (m, 4H, both CH$_3$CH$_2$**CH$_2$**N), 1.86 (m, 2H, CH$_3$**CH$_2$**CH$_2$N), 1.78 (t, 2H, CH$_3$**CH$_2$**CH$_2$N, J = 7.6 Hz), 1.02 (t, 3H, **CH$_3$**CH$_2$CH$_2$N, J = 7.6 Hz), 0.96 (t, 3H, **CH$_3$**CH$_2$CH$_2$N, J = 7.6 Hz); ^{13}C NMR (CDCl$_3$) δ: 166.0 (C=O styrylamido), 159.8 (C-4), 149.9 (C-6), 147.1 (C-2), 141.7 and 119.9 (-**CH**=**CH**-), 134.5, 129.7, 128.8, and 127.8 (aromatics), 89.7 (C-5), 43.8 (CH$_3$CH$_2$**CH$_2$**N), 43.5 (CH$_3$CH$_2$**CH$_2$**N), 21.6 (CH$_3$**CH$_2$**CH$_2$N), 20.2 (CH$_3$**CH$_2$**CH$_2$N), 13.9 (**CH$_3$**CH$_2$CH$_2$N), 11.5 (**CH$_3$**CH$_2$CH$_2$N); IR $\overline{v}_{max}$: 3024, 2962, 1735, 1705, 1651, 972; UV (EtOH) $\lambda_{max}(\varepsilon)$: 279(9130).

3) (E)-6-amino-1-butyl-3-propyl-8-styryluracil (10c)

Yield: 66%; mp 273°C - 274°C; ^{1}H-NMR (CDCl$_3$) δ: 8.14 (b, 1H, N-**H** styrylamido), 7.55 (d, 1H, Ph-**CH**=, J = 15.3 Hz), 6.76 (d, 1H, =**CH**-, J = 15.3 Hz), 7.30 (m, 5H, arom.), 5.82 (b, 2H, -N**H$_2$**), 3.78, (m, 4H, CH$_3$CH$_2$**CH$_2$**N and CH$_3$CH$_2$CH$_2$**CH$_2$**N), 1.58 (m, 4H, CH$_3$**CH$_2$**CH$_2$N and CH$_3$**CH$_2$**CH$_2$CH$_2$N), 1.36 (m, 2H, CH$_3$CH$_2$**CH$_2$**CH$_2$N), 0.91 (t, 3H, **CH$_3$**CH$_2$CH$_2$N, J = 7.3 Hz), 0.88 (t, 3H, **CH$_3$**CH$_2$CH$_2$CH$_2$N, J = 7.3 Hz); ^{13}C NMR (CDCl$_3$) δ: 165.9 (C=O styrylamido), 160.1 C-4), 160.1 (C-4), 150.1 (C-6), 148.5 (C-2), 142.2 and 119.9 (**CH**=**CH**), 134.5, 130.1, 128.9, and 128.0 (aromatics), 92.1 (C-5), 43.4 (CH$_3$CH$_2$CH$_2$**CH$_2$**N), 43.2 (CH$_3$CH$_2$**CH$_2$**N), 30.1 (CH$_3$CH$_2$**CH$_2$**CH$_2$N), 21.6 (CH$_3$**CH$_2$**CH$_2$CH$_2$N), 21.2 (CH$_3$**CH$_2$**CH$_2$N), 13.8 (**CH$_3$**CH$_2$CH$_2$N), 11.4 (**CH$_3$**CH$_2$CH$_2$CH$_2$N); IR $\overline{v}_{max}$:

3319, 1731, 1652, 969; UV (EtOH) $\lambda_{max}(\varepsilon)$: 279(8525).

4) (E)-6-amino-1-pentyl-3-propyl-8-styryluracil (10d)

Yield: 70%; mp 258°C - 260°C; ^{1}H-NMR (CDCl$_3$) δ: 8.04 (b, 1H, N-**H** styrylamido), 7.63 y 6.70 (d, 1H, **CH=CH**, J_{trans} = 15.6 Hz), 7.35 (m, 5H, aromatics), 5.08 (b, 2H, -N**H**$_2$), 4.28, (t, 2H, Bu**CH$_2$**N, J = 7.2 Hz), 4.12 (t, 2H, CH$_3$CH$_2$**CH$_2$**N, J = 7.6 Hz), 1.79 (m, 4H, CH$_3$**CH$_2$**CH$_2$N and Pr**CH$_2$**CH$_2$N, J = 7.6 Hz), 1.42 (t, 3H, **CH$_3$**CH$_2$CH$_2$N, J = 7.2 Hz); 0.97 (sx, 2H, Me**CH$_2$**CH$_2$CH$_2$N), 0.87 (t, 3H, **CH$_3$**CH$_2$CH**$_2$**CH$_2$CH$_2$N, J = 7.6 Hz); ^{13}C NMR (CDCl$_3$) δ: 166.0 (C=O styrylamido), 160.35 (C-4), 152.5 (C-6), 150.8 (C-2), 141.7 and 119.8 (**CH=CH**), 134.3, 129.6, 128.5, and 127.7 (aromatics), 95.4 (C-5), 43.4 (CH$_3$CH$_2$**CH$_2$**N), 39.2 (Bu**CH$_2$**N), 21.1 (CH$_3$**CH$_2$**CH$_2$N), 18.5 (Pr**CH$_2$**CH$_2$N), 13.5 (Et**CH$_3$**CH$_2$CH$_2$N), 11.7 (**CH$_3$**CH$_2$CH$_2$N) 11.4 (**CH$_3$**CH$_2$CH$_2$CH$_2$CH$_2$N); IR $\bar{v}_{max}$: 3165, 1734 1651, 968; UV (EtOH) $\lambda_{max}(\varepsilon)$: 278(11620).

2.1.6. General Procedure for the Preparation of 3-Substituted (E)-1-propyl-8-styrylxanthines (11a-d)

Compounds **10a-d** (1 mmol) were dissolved in a mixture of CH$_3$OH (15 mL) and 20% aq KOH (5 mL) and solutions were refluxed for 3 h. The reaction was followed by TLC (eluent: acetone: hexane 2:3) and UV spectroscopy. After addition of conc. HCl (10 mL) a precipitate was obtained. The suspension was concentrated under vacuum. The precipitate was collected by filtration and washed with a small amount of cold water and MeOH.

1) (E)-3-ethyl-1-propyl-8-styrylxanthine (11a)

Yield: 65%; mp 277°C - 278°C (MeOH); ^{1}H-NMR (CDCl$_3$) δ: 13.60 (bs, 1H, N-**H**), 7.67 and 7.07 (d, 1H, **CH=CH**, J_{trans} = 16.4 Hz), 7.42 (m, 5H, aromatics), 4.07 (q, 2H, Me**CH$_2$**N, J = 7.4 Hz), 3.85 (t, 3H, Et**CH$_2$**N, J = 7 Hz), 1.58 (m, 2H, Me**CH$_2$**CH$_2$N), 1.25 (t, 3H, **CH$_3$**CH$_2$N, J = 7 Hz), 0.87 (t, 3H, **CH$_3$**CH$_2$CH$_2$N, J = 7 Hz); ^{13}C NMR (CDCl$_3$) δ: 154.5 (C-6), 151.0 (C-4), 150.2 (C-8), 148.6 (C-2), 135.9 and 116.2 (**CH=CH**), 135.7, 129.7, 129.6, and 127.7 (aromatics), 107.7 (C-5), 42.7 (Et**CH$_2$**N), 38.8 (Me**CH$_2$**N), 21.4 (Me**CH$_2$**CH$_2$N), 13.7 (**CH$_3$**CH$_2$N), 11.8 (**CH$_3$**CH$_2$CH$_2$N); IR $\bar{v}_{max}$: 3318, 3187, 1648; UV $\lambda_{max}(\varepsilon)$: 343(8660). Anal. Calcd for C$_{18}$H$_{20}$N$_4$O$_2$: C, 66.65; H, 6.21; N, 17.27; Found: C, 66.51; H, 6.09; N, 17.01.

2) (E)-1,3-dipropyl-8-styrylxanthine (11b)

Yield: 72%; mp 267°C - 269°C (MeOH); ^{1}H-NMR (CDCl$_3$) δ: 13.10 (bs, 1H, N-**H**), 7.80 and 7.13 (d, 1H, **CH=CH**, J_{trans} = 16.4 Hz), 7.40 (m, 5H, aromatics), 4.14 (m, 4H, both CH$_3$CH$_2$**CH$_2$**N), 1.85 (m, 2H, CH$_3$**CH$_2$**CH$_2$N^1), 1.76 (m, 2H, CH$_3$**CH$_2$**CH$_2$N^3), 0.99 (m, 6H, both **CH$_3$**CH$_2$CH$_2$N); ^{13}C NMR (CDCl$_3$) δ: 155.9 (C-6), 151.1 (C-4), 150.2 (C-8), 145.7 (C-2), 137.1 and

115.3 (**CH=CH**), 135.7, 129.4, 128.9, and 127.3 (aromatics), 107.2 (C-5), 45.5 (CH$_3$CH$_2$**CH$_2$**N^1), 38.8 (CH$_3$CH$_2$**CH$_2$**N^3), 21.4 (both CH$_3$**CH$_2$**CH$_2$N), 11.5 (**CH$_3$**CH$_2$CH$_2$N^1), 11.3 (**CH$_3$**CH$_2$CH$_2$N^3); IR (KBr) $\bar{v}_{max}$: 3318, 3187, 2961, 1702, 1651; UV (EtOH) $\lambda_{max}(\varepsilon)$: 342(3585); Anal. Calcd for C$_{19}$H$_{22}$N$_4$O$_2$: C, 67.44; H, 6.55; N, 16.56; Found: C, 66.28; H, 6.48; N,16.37.

3) (E)-3-butyl-1-propyl-8-styrylxanthine (11c)

Yield: 69%; mp 278°C - 279°C (MeOH); ^{1}H-NMR (CDCl$_3$) δ: 13.20 (bs, 1H, N-**H**), 7.77 and 7.09 (d, 1H, **CH=CH**, J_{trans} = 16.4 Hz), 7.36 (m, 5H, aromatics), 4.19 (t, 2H, Pr**CH$_2$**N, J = 7.4 Hz), 4.11 (t, 2H, Et**CH$_2$**N, J = 7.4 Hz), 1.80 (m, 4H, Et**CH$_2$**CH$_2$N and Me**CH$_2$**CH$_2$N), 1.43 (m, 2H, Me**CH$_2$**CH$_2$CH$_2$N), 0.99 (m, 6H, both **CH$_3$**CH$_2$CH$_2$CH$_2$N); ^{13}C NMR (CDCl$_3$) δ: 156.0 (C-6), 151.4 (C-4), 150.9 (C-8), 149.9 (C-2), 137.0 and 115.4 (**CH=CH**), 135.7, 129.4, 128.9, and 127.3 (aromatics), 107.4 (C-5), 43.8 (Pr**CH$_2$**N), 43.6 (Et**CH$_2$**N), 30.2 (Et**CH$_2$**CH$_2$N), 21.5 (Me**CH$_2$**CH$_2$CH$_2$N), 20.1 (Me**CH$_2$**CH$_2$N), 13.9 (**CH$_3$**CH$_2$CH$_2$CH$_2$N), 11.5 (**CH$_3$**CH$_2$CH$_2$N); IR (KBr) $\bar{v}_{max}$: 3318, 2958, 1702, 1649; UV (EtOH) $\lambda_{max}(\varepsilon)$: 342(8785); Anal. Calcd for C$_{20}$H$_{24}$N$_4$O$_2$: C, 68.16; H, 6.86; N, 15.90; Found: C, 68.03; H, 6.89; N, 15.77.

4) (E)-3-pentyl-1-propyl-8-styrylxanthine (11d)

Yield: 66%; 224°C - 226°C; ^{1}H-NMR (CDCl$_3$) δ: 13.57 (bs, 1H, N-**H**), 7.63 and 7.06 (d, 1H, **CH=CH**, J_{trans} = 16.4 Hz), 7.40 (m, 5H, aromatics), 4.01 (t, 2H, Bu**CH$_2$**N, J = 7 Hz), 3.85 (t, 2H, Et**CH$_2$**N, J = 7 Hz), 1.70 (m, 2H, Pr**CH$_2$**CH$_2$N), 1.56 (m, 2H, Me**CH$_2$**CH$_2$N), 1.31 (m, 4H, Me**CH$_2$CH$_2$**CH$_2$CH$_2$N), 0.87 (m, 6H, **CH$_3$**(CH$_2$)$_4$N and **CH$_3$**(CH$_2$)$_2$N); ^{13}C-NMR (CDCl$_3$) δ: 154.4 (C-6), 151.2 (C-4), 150.1 (C-8), 148.9 (C-2), 138.9 and 116.4 (**CH=CH**), 135.7, 129.7, 129.5, and 127.7 (aromatics), 107.6 (C-5), 43.4 (Bu**CH$_2$**N), 42.7 (Et**CH$_2$**N), 28.8 (Pr**CH$_2$**CH$_2$N), 27.7 (Et**CH$_2$**(CH$_2$)$_2$N), 22.3 (Me**CH$_2$**(CH$_2$)$_3$N), 21.4 (Me**CH$_2$**CH$_2$N), 14.4 (**CH$_3$**CH$_2$CH$_2$N), 11.7 (**CH$_3$**(CH$_2$)$_4$N); IR (KBr) $\bar{v}_{max}$: 3318, 2958, 1702, 1649; UV (EtOH) $\lambda_{max}(\varepsilon)$: 347(5520); Anal. Calcd for C$_{21}$H$_{26}$N$_4$O$_2$: C, 68.82; H, 7.15; N, 15.28; Found: C, 68.70; H, 7.01; N, 15.15.

2.2. Binding Studies

Radioligand binding studies to determine the relative affinity of compounds **11a-d** to A_1 and A_{2A} adenosine receptors were made using crude membrane preparations of rat cortical membrane and rat striatal membrane as previously described [29]. [^{3}H]-2-chloro-N^6-cyclopentyladenosine ([^{3}H]CCPA) was used as A_1 receptor ligand and [^{3}H]-(E)-3-(3-hydroxypropyl)-8-(3-methoxystyryl)-7-ethyl-1-propargylxanthine (MSX-2) as A_{2A} receptor ligand. Radiolabelled compounds were purchased from NEN Life Sciences, Dreieich, Germany.

2.3. Rotational Behavior in Rats with a Unilateral Lesion Caused by 6-Hydroxydopamine

All procedures described in this study were approved by the BUAP Animal Care Committee and met governmental guidelines (Mexican Council for Animal Care, Norma.

Oficial Mexicana NOM-062-ZOO-1999). Male Wistar rats (from Bioterio Claude Bernard, BUAP) weighed 250 - 350 g at the beginning of the experiment. Animals were housed in pairs in ventilated sound-attenuated rooms under a 12 h light:dark cycle at an ambient temperature with free access to water and food. The animals were deeply anaesthetized with choral hydrate (350 mg/kg ip) and received an injection of 2 µL 6-hydroxydopamine (6-OHDA) over a period of 10 min (8 µg/µL dissolved in 0.1% ascorbic acid) into the left *substantia nigra pars compacta* (SNc), according to the atlas of Paxinos and Watson 1998 [30] (stereotaxic coordinates; A = 4.0 mm anterior to bregma, L = 1.3 mm side lateral to the midline, V = 6.5 below the skull) to produce a unilateral dopamine depletion.

Two weeks after the lesion caused by the 6-OHDA the rats were evaluated with methamphetamine (METH, 7 mg/kg sc) starting 10 minutes after injection. To measure turning behavior the rats were placed in a plastic chamber and the number of complete (360°) turns, made over a period of 10 minutes, were counted. The mean number of ipsilateral rotations per minute was measured. This model is the one of the most reliable rodent models for the assessment of anti-Parkinsonian activity of the news drugs [31]. Only animals exhibiting at least 10 ipsilateral rotations/minute were used in subsequent experiments.

Ten days after the first evaluation of the turning behavior, the animals were administrated with (*E*)-3-ethyl-1-propyl-8-styrylxanthine (A15Et, **11a**) or (*E*)-3-butyl-1-propyl-8-styrylxanthine (A15Bu, **11c**) at dose of 1 mg/kg sc or with vehicle (mineral oil + DMSO, 0.1 ml/100 g sc), and 10 min later the animals received METH (7 mg/kg sc) and a second turning behavior was evaluated over a period of 80 min.

2.4. Statistical Analysis

The results were expressed as the mean ± SEM. The statistical analysis for turning behavior was done using *t* of student, with $p < 0.05$ consider significant.

3. Results

3.1. Chemistry

The synthesis of the compounds **11a-d** was accomplished following the general pathway [25,32,33] depicted in the **Scheme 1**, optimizing all involved reactions.

The alkylation of the N atom at position 3 in the 6-aminouracil (**5**) was highly selective using the known "one pot" procedure [32]: trisilylation of **5** by means of hexamethyldisilazane (HMDS), followed by a typical N-alkylation using an alkyl iodide. We have obtained excellent yields using small quantities of HMDS. The identification of the 3-substituted 6-aminouracil was carried out through the analysis of the chemical shift of the signal for NH_2 protons in the ^{1}H-NMR spectrum: in the 6-amino-1-propyluracil the NH_2 protons are shifted downfield with respect of those in 6-aminouracil; in the 6-amino-3-propyluracil the NH_2 protons are not influenced [34]. The UV spectrum showed the classical absorption of a β-amino α,β-unsaturated carbonyl (λ_{max} 261 nm).

In the preparation of the 6-amino-5-nitroso-3-propyluracil (**7**) better results were obtained when only 2 eq of sodium nitrite were used, working at room temperature. The yellow compound **7** (λ_{max} 320 nm) was isolated in 85% yield. In the ^{13}C-NMR spectrum the signal for C-5 appears at 140.3 ppm, down-shifted in comparison to that in the starting material (74.6 ppm), caused by the electron-withdrawing effect of the nitroso group. In the IR spectra the characteristic band for the N=O group is shown at 1510 cm^{-1}.

The nitroso compound **6** was chemoselectively reduced by sodium dithionite in alkaline solution to the corresponding 5,6-diamino-3-propyluracil (**8**). It was easily isolated and was used for the next step without further purification because of its instability to light, oxygen and acidic medium. The chemoselective reduction was carried out in the range from 40°C to 80°C; we found that at lower temperatures the reaction needs a huge excess of reducing agent, causing difficulties in the purification of the diamino compound **8**. For this reaction, we additionally examined the influence of the concentration of ammonia. All concentrations used (24%, 12%, 6% and 3%) led successfully to the diamino compound **8** in about 70% yield.

The condensation of the diamino compound **8** with cinnamic acid to form (*E*)-6-amino-3-propyl-5-styrylcarboxamidouracil (**9**) was achieved using N-ethyl-N'-[3-(dimethylamino)propyl]carbodiimide (EDC) as the coupling agent. The configuration of the double bond in the styryl moiety was corroborated by its ^{1}H-NMR spectrum: the doublet signal at 6.85 ppm, assigned to vinyl proton, has a typical J_{trans} = 16 Hz. The alkylation at N^1 of the uracil derivative **9** could easily be performed under mild conditions. A DMF solution of **9**, treated with K_2CO_3 and an alkyl bromide or iodide, yielded the 1-substituted (*E*)-6-amino-3-propyl-5-styrylcarboxamidouracil **10a-d** in good yields. UV absorptions are in the range of 278 - 280 nm. No alkylation at position 7 was observed.

Finally, an alkaline treatment promoted the cyclization

Reagents: i. HMDS, $(NH_4)_2SO_4$, n-Pr-I; ii. $NaNO_2$, AcOH; iii. $Na_2S_2O_4$, NH_4OH; iv. $C_9H_8O_2$, CH_3OH; v. R-X, DMF, K_2CO_3; vi. KOH, CH_3OH.

Scheme 1. Synthetic pathway for the styrylxanthines 11a-d.

between the amino and carboxamido groups to provide compounds **11a-d**, in around 70% yield. The UV spectra showed bands in the range λ_{max} = 342 - 347 nm, characteristic for 8-styrylxanthines.

3.2. Binding Studies

The results of binding studies showed that all the 1,3-disubstituted 8-styrylxanthines synthetized have affinity to both adenosinergic receptors. **Table 1** shows the different affinities of each compound analyzed; it is worth to notice that gradual increase in the length of the carbon chain of the alkyl group at the N atom at position 3 increases the affinity towards A_1 receptors. However, opposite effect is observed for affinity toward A_{2A} receptors.

3.3. Behavioral Test Method

In these conditions the animals showed a clear increase in the turning behavior 14.21 ± 3.206 minutes after METH injection. The difference was stable over a period of 80 minutes with a significant decrease of 1.938 ± 0.6003 minutes respect to group that only received to vehicle (mineral oil + DMSO; 1:1). Animals that only received vehicle did not show deficit in movement initiation or speed of turning (**Figure 2**).

Based on binding studies we evaluated the effect on turning behavior of (*E*)-3-ethyl-1-propyl-8-styrylxanthine (A15Et, **11a**), compound that showed highest affinity towards A_{2A} receptor and also (*E*)-3-butyl-1-propyl-8-styrylxanthine (Al5Bu, **11c**) with approximately half affinity to A_{2A} receptor (see **Table 1**).

Table 1. Adenosine receptor affinities of 3-substituted (*E*)-1-propyl-8-styrylxanthines.

Compound	Ki (nM)	
	A_1 Affinity rat brain cortical membranes [³H]CCPA	A_{2A} Affinity rat brain striatal membranes [³H]MSX-2
11a	14.50 ± 1.50 (n = 2)	12.5 ± 0.5 (n = 2)
11b	13.67 ± 0.88 (n = 3)	12.97 ± 1.5 (n = 3)
11c	7.05 ± 0.25 (n = 2)	24.0 ± 8.0 (n = 2)
11d	6.30 ± 1.10 (n = 2)	26.0 ± 2 (n = 2)

Ki [nM] ± SEM or % displacement at concentration indicated.

Figure 2. The ipsilateral turn behavior were induced by administration of METH (7 mg/kg sc) in rats with 6-OHDA. The turns/min were counted over 10 minutes. The arrow indicates the administration time. Each point represents the mean number of ipsilateral turns each 10 min ± SEM. Vehicle (Δ) and 6-OHDA (○).

The A15Et decreased the turning behavior and was administrated as a dose of 1 mg/Kg, 30 minutes before the administration of METH (7 kg/kg sc). This significant difference was maintained over a period of 50 minutes respect to the vehicle group (**Figure 3(a)**).

The Al5Bu was administrated 30 min before the METH (7 mg/kg sc), decreased significantly the turning behavior and this difference was maintained over a period of 50 - 70 min respect to the vehicle group (**Figure 3(b)**).

4. Discussion

The administration of the A15Et (11a) or Al5Bu (11c) effectively reduces the ipsilateral turning behavior caused by METH in rats with unilaterally lesions caused by 6-OHDA. These compounds can exert significant functional effects on motor behavior. Also we have found that rotational asymmetry in rats with unilateral lesions caused by 6-OHDA can be counteract by administration of compounds A15Et and A15Bu (**Figures 3(a)** and **(b)**). These effects were more potent and with more prolonged duration with A15Et, this effect was expected in order


Figure 3. Effect of (a) A15Et and (b) A15Bu on number of ipsilateral turns in rats with unilateral lesions caused by 6-OHDA. Both novel xanthines were administrated at dose of 1 mg/kg sc 10 min before the administration of METH (7 mg/kg sc). Open bars represent ipslateral turns in the vehicle group and hatched bars show the turns with derivates of xanthines. The data were given as the mean ± SEM. The statistical analysis was made using *t* of student test. ${}^{*}p < 0.05$ vs Vehicle/METH group.

that A15Et showed highest affinity to A_{2A} receptor and this effect may be related to modulation of A_{2A} receptor over D_2 receptor. Recently it has been reported that other compounds possessing the property of adenosine A_{2A}-receptor antagonism [35,36], improved the motor effect in an experimental model of Parkinson's disease [37]. Because adenosine A_{2A} receptors have a profound influence on motor functions via the modulation of basal ganglia output pathways [37], blockade of this modulatory function by an A_{2A} antagonist could repair striatopallidal abnormal-neuronal activities caused by striatal dopamine depletion in the Parkinsonian state [37].

5. Conclusion

In summary, we describe the synthesis of the 1,3-disubstituted 8-styrylxanthines **11a-d** with optimized conditions and excellent yield. The results of the present study provide evidence that all compounds synthetized have affinity towards A_1 and A_{2A} receptors but compound A15Et showed the highest affinity towards A_{2A} receptor. The administration of the A15Et (11a) or Al5Bu (11c) effectively reduces the ipsilateral turning behavior caused by METH in rats with unilaterally lesions caused by 6-OHDA. Based on these results we propose to A15Et as a potential compound to treat some symptoms of Par-

kinson's disease.

6. Acknowledgements

REFERENCES

[1]   R. A. Olsson and J. D. Pearson, "Cardiovascular Purinocaptors," *Physiological Reviews*, Vol. 70, No. 3, 1990, pp. 761-845.

[2]   C. Londos, D. M. Cooper and J. Wolff, "Subclasses of External Adenosine Receptors," *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 77, No. 5, 1980, pp. 2551-2554. doi:10.1073/pnas.77.5.2551

[3]   B. B. Fredholm, M. P. Abbracchio, G. Burnstock, J. W. Daly, T. K. Harden, K. A. Jacobson, P. Leff and M. Williams, "Nomenclature and Classification of Purinoceptors," *Pharmacological Reviews*, Vol. 46, No. 2, 1994, pp. 143-156.

[4]   B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, J. Linden and C. E. Müller, "International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update," *Pharmacological Reviews*, Vol. 63, No. 1, 2011, pp. 1-34. doi:10.1124/pr.110.003285

[5]   D. L. Rosin, A. Robeva, R. L. Woodard, P. G. Guyenet and J. Linden, "Immunohistochemical Localization of Adenosine Receptors in the Rat Nervous System," *The Journal of Comparative Neurology*, Vol. 401, No. 2, 1998, pp. 163-186. doi:10.1002/(SICI)1096-9861(19981116)401:2<163::AID-CNE2>3.0.CO;2-D

[6]   P. Svenningsson, C. Le Moine, B. Kull, R. Sunahara, B. Bloch and B. B. Fredholm, "Cellular Expression of Adenosine A_{2A} Receptor Messenger RNA in the Rat Nervous System with Special Reference To Dopamine Innervated Areas," *Neuroscience*, Vol. 80, No. 4, 1997, pp. 1171-1185. doi:10.1016/S0306-4522(97)00180-2

[7]   J. Shimada and F. Suzuki, "Medicinal Chemistry of Adenosine Receptors in the Brain and Periphery," In: H. Hiroshi, P. J. Richardson and P. Jenner, Eds., *Adenosine Receptors and Parkinson's Disease*, Academic Press, New York, 2000, pp. 31-50. doi:10.1016/B978-012400405-4/50004-6

[8]   S Ferré, G. von Euler, B. Johansson, B. B. Fredholm and K. Fuxe, "Stimulation of High-Affinity Adenosine A2 Receptors Decreases the Affinity of Dopamine D2 Receptors in Rat Striatal Membranes," *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 88, No. 16, 1991, pp. 7238-7241. doi:10.1073/pnas.88.16.7238

[9]   J. D. Peterson, J. A. Goldberg and D. J. Surmier, "Adenosine A2a Receptor Antagonists Attenuate Striatal Adaptations Following Dopamine Depletion," *Neurobiology of Disease*, Vol. 45, No. 1, 2012, pp. 401-416. doi:10.1016/j.nbd.2011.08.030

[10] P. Jenner, "Istradefylline, a Novel Adenosine A_{2A} Receptor Antagonist, for the Treatment of Parkinson's Disease," *Expert Opinion on Investigational Drugs*, Vol. 14, No. 6, 2005, pp. 729-738. doi:10.1517/13543784.14.6.729

[11] M. T. Armentero, A. Pinna, S. Ferré, J. L. Lanciego, C. E. Müller and R. Franco, "Past, Present and Future of A_{2A} Adenosine Receptor Antagonists in Therapy of Parkinson's Disease," *Pharmacology and Therapeutics*, Vol. 132, No. 3, 2011, pp. 280-299. doi:10.1016/j.pharmthera.2011.07.004

[12] N. Szabó, Z. T. Kincses and L. Vécsei, "Novel Therapy in Parkinson's Disease: Adenosine A_{2A} Receptor Antagonists," *Expert Opinion on Drug Metabolism and Toxicology*, Vol. 7, No. 4, 2011, pp. 441-455. doi:10.1517/17425255.2011.557066

[13] N. Castagnoli Jr., J. P. Petzer, S. Steyn, K. Castagnoli, J. F. Chen, M. A. Schwarzschild and C. J. Van der Schyf, "Monoamine Oxidase B Inhibition and Neuroprotection: Studies on Selective Adenosine A_{2A} Receptor Antagonists," *Neurology*, Vol 61, No. 11, 2003, pp. S62-S68. doi:10.1212/01.WNL.0000095215.97585.59

[14] P. Popoli, C. Frank, M. T. Tebano, R. L. Potenza, A. Pintor, M. R. Domenici, V. Nazzicone, A. Pèzzola and R. Reggio, "Modulation of Glutamate Release and Excitotoxicity by Adenosine A_{2A} Receptors," *Neurology*, Vol. 61, No. 11, 2003, pp. S69-S71. doi:10.1212/01.WNL.0000095216.89483.A2

[15] J. P. Petzer, S. Steyn, K. P. Castagnoli, J. F. Chen, M. A. Schwarzchild, C. J. Van der Schyf and N. Castagnoli, "Inhibition of Monoamine Oxidase B by Selective Adenosine A_{2A} Receptor Antagonists," *Bioorganic & Medicinal Chemistry*, Vol. 11, No. 7, 2003, pp. 1299-1310. doi:10.1016/S0968-0896(02)00648-X

[16] P. Hickey and M. Stacy, "Adenosine A2A Antagonists in Parkinson's Disease: What's Next?" *Current Neurology and Neuroscience Reports*, Vol. 12, No. 4, 2012, pp. 376-385. doi:10.1007/s11910-012-0279-2

[17] A. H. Schapira, E. Bezard, J. Brotchie, F. Calon, G. L. Collingridge, B. Ferrer, B. Hengerer, E. Hirsch, P. Jenner, N. Le Novère, J. A. Obeso, M. A. Schwarzschild, U. Spampinato and G. Davidai, "Novel Pharmacological Targets for the Treatment of Parkinson's Disease,z" *Nature Reviews*, *Drug Discovery*, Vol. 5, No. 10, 2006, pp. 845-854. doi:10.1038/nrd2087

[18] J. Bove, J. Serrats, G. Mengod, R. Cortés, E. Tolosa and C. Marin, "Neuroprotection Induced by Adenosine A_{2A} Antagonist CSC in the 6-OHDA Rat Model of Parkinsonism: Effect on the Activity of Striatal Output Pathways," *Experimental Brain Research*, Vol 165, No. 3, 2005, pp. 362-374. doi:10.1007/s00221-005-2302-1

[19] W. Bara-Jiminez, A. Sherzai, T. Dimitrova, A. Favit, F. Bibbiani, M. Gillespie, M. J. Morris, M. M. Mouradian and T. N. Chase, "Adenosine A_{2A} Receptor Antagonist Treatment of Parkinson's Disease," *Neurology*, Vol. 61, No. 3, 2003, pp. 293-296. doi:10.1212/01.WNL.0000073136.00548.D4

[20] N. Vlok, S. F. Malan, N. Castagnoli Jr., J. J. Bergh and J. P. Petzer, "Inhibition of Monoamine Oxidase B by Analogues of the Adenosine A$_{2A}$ Receptor Antagonist (E)-8-(3-chlorostyryl)caffeine (CSC)," *Bioorganic & Medicinal Chemistry*, Vol. 14, No. 10, 2006, pp. 3512-3521. doi:10.1016/j.bmc.2006.01.011

[21] M. B. Youdim and P. F. Riederer, "A Review of the Mechanisms and Role of Monoamine Oxidase Inhibitors in Parkinson's Disease, " *Neurology*, Vol. 63, No. 7, 2004, pp. S32-S35. doi:10.1212/WNL.63.7_suppl_2.S32

[22] M. A. Schwarszchild, J. F. Chen and A. Ascherio, "Caffeinated Clues and the Promise of Adenosine A$_{2A}$ Antagonists in PD," *Neurology*, Vol. 58, No. 8, 2002, pp. 1154-1160. doi:10.1212/WNL.58.8.1154

[23] A. Muñoz-Zurita, J. Sandoval-Ramírez, L. E. Espinoza-Moreno, C. Parra-Cid, L. A. Juárez-Leyva, D. Limón-Pérez de León and G. Flores, " Synthesis and Evaluation of Ansiolytic Effect of a New Derivate Pirimide [1,6-a] Pirimidinic," *Revista de la Sociedad Química de México*, Vol. 47, No. 4, 2003, pp. 298-302.

[24] C. B. Vu, D. Pan, B. Pen, G. Kumaravel, G. Smits, X. Jin, D. Phadke, T. Engber, C. Huang, J. Reilly, S. Tam, D. Grant, G. Hetu and R. C. Petter, "Novel Diamino Derivates of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as Potent and Selective Adenosine A$_{2a}$ Receptor Antagonists," *Journal of Medicinal Chemistry*, Vol. 48, No. 6, 2005, pp. 2009-2018. doi:10.1021/jm0498396

[25] S. Massip, J. Guillon, D. Bertarelli, J. J. Bosc, J. M. Léger, S. Lacher, C. Bontemps, T. Dupont, C. E. Mulle and C. Jarry, "Synthesis and Preliminary Evaluation of New 1- and 3-[1-(2-Hydroxy-3-phenoxypropyl)]xanthines from 2-Amino-2-oxazolines as Potential A$_1$ and A$_{2A}$ Adenosine Receptor Antagonists," *Bioorganic & Medicinal Chemistry*, Vol. 14, No. 8, 2006, pp. 2697-2719. doi:10.1016/j.bmc.2005.11.050

[26] K. A. Jacobson, C. Gallo-Rodriguez, N. Melman, B. Fischer, M. Maillard, A. van Bergen, P. J. van Galen and Y. Karton, "Structure-Activity Relationships of 8-Styrylxanthines as A2-Selective Adenosine Antagonists," *Journal of Medicinal Chemistry*, Vol. 36, No. 10, 1993, pp. 1333-1342. doi:10.1021/jm00062a005

[27] M. Williams, "Purinergic Pharmaceuticals for the 1990," *Nucleosides and Nucleotides*, Vol. 10, No. 5, 1991, pp. 1087-1099. doi:10.1080/07328319108047246

[28] C. E. Müller, J. Maurinsh and R. Sauer, "Binding of

[^{3}H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to Rat Striatal Membranes—A New, Selective Antagonist Radioligand for A(2A) Adenosine Receptors," *European Journal of Pharmaceutical Sciences*, Vol. 10, No. 4, 2000, pp. 259-265. doi:10.1016/S0928-0987(00)00064-6

[29] A. Galvan, B. Floran, D. Erlij, J. Aceves, "Intrapallidal Dopamine Restores Motor Deficits Induced by 6-Hydroxydopamine in the Rat," *Journal of Neural Transmission*, Vol. 108, No. 2, 2001, pp. 153-166. doi:10.1007/s007020170085

[30] G. Paxinos and C. Watson, "The Rat Brain in Stereotaxic Coordinates," Academic Press, San Diego, 1998.

[31] U. Ungerstedt and G. W. Arbuthnott, "Quantitative Recording of Rotational Behavior in Rats after 6-Hydroxy-Dopamine Lesions of the Nigrostriatal Dopamine System," *Brian Research*, Vol. 24, No. 3, 1970, pp. 485-493. doi:10.1016/0006-8993(70)90187-3

[32] C. E. Müller, "Synthesis of 3-Substituted 6-aminouracils," *Tetrahedron Letters*, Vol. 32, No. 45, 1991, pp. 6539-6540. doi:10.1016/0040-4039(91)80214-Q

[33] C. E. Müller, "A2A Adenosine Receptor Antagonists—Future Drugs for Parkinson's Disease?" *Drugs of the Future*, Vol. 25, No. 10, 2000, p. 1043. doi:10.1358/dof.2000.025.10.858696

[34] C. E. Müller and J. Sandoval-Ramírez, "A New Versatile Synthesis of Xantines with Variable Substituents in the 1-, 3-, 7- and 8-Positions," *Synthesis*, Vol. 1995, No. 10, 1995, pp. 1295-1299. doi:10.1055/s-1995-4082

[35] M. Ochi, K. Koga, M. Kurokawa, H. Kase, J. Nakamura and Y. Kuwana, "Systemic Administration of Adenosine A$_{2A}$ Receptor Antagonist Reverses Increased GABA Release in the Globus Pallidus of Unilateral 6-Hydroxydopamine-Lesioned Rats: A Microdialysis Study," *Neuroscience*, Vol. 100, No. 1, 2000, pp. 53-62. doi:10.1016/S0306-4522(00)00250-5

[36] H. Kase, "New Aspects of Physiological and Pathophysiological Functions of Adenosine A2A Receptor in Basal Ganglia," *Bioscience, Biotechnology and Biochemistry*, Vol. 65, No. 7, 2001, pp. 1447, 1457.

[37] F. Pedata, A. M. Pugliese, A. Melani and M. Gianfriddo, "A$_{2A}$ Receptors in the Neuroprotection of Dopaminergic Neurons," *Neurology*, Vol. 61, No. 11, 2003, pp. S49-S50. doi:10.1212/01.WNL.0000095212.19029.04